Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies

Heavy chain-only antibodies (HCAbs) do not associate with light chains and their VH regions are functional as single domains, forming the smallest active antibody fragment. These VH regions are ideal building blocks for a variety of antibody-based biologics because they tolerate fusion to other molecules and may also be attached in series to construct multispecific antibodies without the need for protein engineering to ensure proper heavy and light chain pairing. Production of human HCAbs has been impeded by the fact that natural human VH regions require light chain association and display poor biophysical characteristics when expressed in the absence of light chains. Here, we present an innovative platform for the rapid development of diverse sets of human HCAbs that have been selected in vivo. Our unique approach combines antibody repertoire analysis with immunization of transgenic rats, called UniRats, that produce chimeric HCAbs with fully human VH domains in response to an antigen challenge. UniRats express HCAbs from large transgenic loci representing the entire productive human heavy chain V(D)J repertoire, mount robust immune responses to a wide array of antigens, exhibit diverse V gene usage and generate large panels of stable, high affinity, antigen-specific molecules.

[1]  Michael J. Osborn,et al.  Sequence-Based Discovery Demonstrates That Fixed Light Chain Human Transgenic Rats Produce a Diverse Repertoire of Antigen-Specific Antibodies , 2018, Front. Immunol..

[2]  W. Richards,et al.  A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity , 2018, The Journal of Biological Chemistry.

[3]  Conor McMahon,et al.  Yeast surface display platform for rapid discovery of conformationally selective nanobodies , 2018, Nature Structural & Molecular Biology.

[4]  Kevin A. Henry,et al.  Stability-Diversity Tradeoffs Impose Fundamental Constraints on Selection of Synthetic Human VH/VL Single-Domain Antibodies from In Vitro Display Libraries , 2017, Front. Immunol..

[5]  Harald Kolmar,et al.  Camelid and shark single domain antibodies: structural features and therapeutic potential. , 2017, Current opinion in structural biology.

[6]  Anke Wienecke-Baldacchino,et al.  Functionally Convergent B Cell Receptor Sequences in Transgenic Rats Expressing a Human B Cell Repertoire in Response to Tetanus Toxoid and Measles Antigens , 2017, bioRxiv.

[7]  F. Tian,et al.  Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential , 2017, International journal of nanomedicine.

[8]  J. Nilvebrant,et al.  Engineered Autonomous Human Variable Domains. , 2017, Current pharmaceutical design.

[9]  N. Trinklein,et al.  A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects , 2016, EBioMedicine.

[10]  C. Chung,et al.  Novel Interaction Mechanism of a Domain Antibody-based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency than Ranibizumab and Bevacizumab and Improved Capacity over Aflibercept* , 2016, The Journal of Biological Chemistry.

[11]  C. Palomo,et al.  Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection , 2015, Antimicrobial Agents and Chemotherapy.

[12]  D. Christ,et al.  Fully Human VH Single Domains That Rival the Stability and Cleft Recognition of Camelid Antibodies* , 2015, The Journal of Biological Chemistry.

[13]  Steven Lantz,et al.  Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies. , 2015, Molecular pharmaceutics.

[14]  C. Barelle,et al.  Shark variable new antigen receptor biologics – a novel technology platform for therapeutic drug development , 2014, Expert opinion on biological therapy.

[15]  D. Christ,et al.  Stability engineering of the human antibody repertoire , 2014, FEBS letters.

[16]  N. Harris,et al.  The heavy chain diseases: clinical and pathologic features. , 2014, Oncology.

[17]  Michael J. Osborn,et al.  Human antibody expression in transgenic rats: comparison of chimeric IgH loci with human VH, D and JH but bearing different rat C-gene regions. , 2013, Journal of immunological methods.

[18]  Xinglong Wang,et al.  Design and Selection of a Camelid Single-Chain Antibody Yeast Two-Hybrid Library Produced De Novo for the Cap Protein of Porcine Circovirus Type 2 (PCV2) , 2013, PloS one.

[19]  Michael J. Osborn,et al.  High-Affinity IgG Antibodies Develop Naturally in Ig-Knockout Rats Carrying Germline Human IgH/Igκ/Igλ Loci Bearing the Rat CH Region , 2013, The Journal of Immunology.

[20]  Ming Lei,et al.  Frontier of therapeutic antibody discovery: The challenges and how to face them. , 2012, World journal of biological chemistry.

[21]  J. Lebbink,et al.  Heavy chain-only antibodies and tetravalent bispecific antibody neutralizing Staphylococcus aureus leukotoxins , 2011, Proceedings of the National Academy of Sciences.

[22]  Nick Deschacht,et al.  A Case Of Convergence: Why Did a Simple Alternative to Canonical Antibodies Arise in Sharks and Camels? , 2011, PLoS biology.

[23]  A. Marco Biotechnological applications of recombinant single-domain antibody fragments , 2011 .

[24]  A. de Marco Biotechnological applications of recombinant single-domain antibody fragments , 2011, Microbial cell factories.

[25]  N. Pannu,et al.  REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.

[26]  M. Son,et al.  Preparing DNA libraries for multiplexed paired-end deep sequencing for Illumina GA sequencers. , 2011, Current protocols in microbiology.

[27]  Kai Lou Crescendo's TKO , 2010 .

[28]  Michael J. Osborn,et al.  Characterization of immunoglobulin heavy chain knockout rats , 2010, European journal of immunology.

[29]  C. Plummer,et al.  Next generation immunotherapeutics--honing the magic bullet. , 2009, Current opinion in biotechnology.

[30]  Ignacio Anegon,et al.  Knockout Rats via Embryo Microinjection of Zinc-Finger Nucleases , 2009, Science.

[31]  M. Seman,et al.  Single domain antibodies: promising experimental and therapeutic tools in infection and immunity , 2009, Medical Microbiology and Immunology.

[32]  Etienne Weiss,et al.  Therapeutic antibodies: successes, limitations and hopes for the future , 2009, British journal of pharmacology.

[33]  S. Muyldermans,et al.  General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold* , 2009, Journal of Biological Chemistry.

[34]  C. J. Bond,et al.  Comprehensive Analysis of the Factors Contributing to the Stability and Solubility of Autonomous Human VH Domains* , 2008, Journal of Biological Chemistry.

[35]  Michael J. Osborn,et al.  Heavy chain–only antibodies are spontaneously produced in light chain–deficient mice , 2007, The Journal of experimental medicine.

[36]  Rodrigo Lopez,et al.  Clustal W and Clustal X version 2.0 , 2007, Bioinform..

[37]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[38]  F. Grosveld,et al.  Generation of heavy-chain-only antibodies in mice , 2006, Proceedings of the National Academy of Sciences.

[39]  David Jung,et al.  Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. , 2006, Annual review of immunology.

[40]  P. Hudson,et al.  Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.

[41]  L. Wyns,et al.  Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. , 2005, Journal of molecular biology.

[42]  Marie-Paule Lefranc,et al.  IMGT , the international ImMunoGeneTics information system , 2003 .

[43]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[44]  Ron D. Appel,et al.  ExPASy: the proteomics server for in-depth protein knowledge and analysis , 2003, Nucleic Acids Res..

[45]  Andreas Plückthun,et al.  Biophysical properties of human antibody variable domains. , 2003, Journal of molecular biology.

[46]  I. Lundkvist,et al.  Long‐term kinetics of adult human antibody repertoires , 2002, Immunology.

[47]  L. Wyns,et al.  Camel Single-domain Antibodies as Modular Building Units in Bispecific and Bivalent Antibody Constructs* , 2001, The Journal of Biological Chemistry.

[48]  O. Britanova,et al.  Amplification of cDNA ends based on template-switching effect and step-out PCR. , 1999, Nucleic acids research.

[49]  Lode Wyns,et al.  Potent enzyme inhibitors derived from dromedary heavy‐chain antibodies , 1998, The EMBO journal.

[50]  R. Brezinschek,et al.  Analysis of the human VH gene repertoire. Differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(-)/IgM+ B cells. , 1997, The Journal of clinical investigation.

[51]  L. Riechmann,et al.  Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability. , 1996, Protein engineering.

[52]  Austin Hughes,et al.  A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks , 1995, Nature.

[53]  L. Riechmann,et al.  ‘Camelising’ human antibody fragments: NMR studies on VH domains , 1994, FEBS letters.

[54]  S. Muyldermans,et al.  Naturally occurring antibodies devoid of light chains , 1993, Nature.

[55]  D. Eisenberg,et al.  Analysis of membrane and surface protein sequences with the hydrophobic moment plot. , 1984, Journal of molecular biology.

[56]  R. Doolittle,et al.  A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.

[57]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .